114 / 160
666
Conclusiones
El éxito de la terapia de los pacientes con EII, depende de la
adecuada valoración de muchos y complejos factores que el
médico debe integrar adecuadamente. Esta revisión destaca
los errores más frecuentes que se cometen en el tratamiento
de pacientes con EII, de modo que estos no sigan repitiéndose.
La constitución de equipos multidisciplinarios para el mejor
control y tratamiento de estos pacientes, es sin duda una nece-
sidad para lograr un mejor resultado en los tratamientos de las
EII cometiendo menos errores (24).
El autor declara no tener conflictos de interés, en relación a este artículo.
REFERENCIAS BIBLIOGRáFICAS
1. Simian D, Estay C, Lubascher J, Acuña R et al. Inflammatory
bowel disease. Experience in 316 patients. Rev Med Chil 2014
Aug; 142(8):1006-13.
2. Burisch J, Munkholm P. The epidemiology of inflammatory
bowel disease. Scand J Gastroenterol. 2015 Feb; 17:1-10.
3. Silverberg MS, Daly MJ, Moskovitz DN et al. Diagnostic
misclassification reduces the ability to detect linkage in
inflammatory bowel disease genetic studies. Gut 2001;
49:773-6.
4. Tysk C, Wickbom A, Nyhlin N, Eriksson S, Bohr J. Recent
advances in diagnosis and treatment of microscopic colitis.Ann
Gastroenterol 2011;24(4):253-262.
5. Tontini GE, Vecchi M, Pastorelli L et al. Differential diagnosis in
inflammatory bowel disease colitis: state of the art and future
perspectives. World J Gastroenterol. 2015 Jan ;21(1):21-46
6. Dubeau MF, Iacucci M, Beck PL et al. Drug induced
inflammatory bowel disease and IBD-like conditions. Inflamm
Bowel Dis. 2013 Feb;19 (2):445-56.
7. Bennike T, Birkelund S, Stensballe A, Andersen V. Biomarkers in
inflammatory bowel diseases: Current status and proteomics
identification strategies. World Journal of Gastroenterology :
WJG. 2014; 20(12):3231-3244.
8. Bayless TM, Harris ML. Inflammatory bowel disease and
irritable bowel syndrome. Med Clin N Am 1990; 74:21–8.
9. Goldstein F, DiMarino AJ. Diarrhea as a side effect of
mesalamine treatment for inflammatory bowel disease. J Clin
Gastroenterol 2000; 31: 60-62.
10. Annesea V, Daperno M, Rutter M et al. European evidence
based consensus for endoscopy in inflammatory bowel disease.
J Crohns Colitis 2013 Dec; 7(12):982-1018.
11. De Melo SW Jr, Di Palma. The role of capsule endoscopy in
evaluating inflammatory bowel disease. Gastroenterol Clin
North Am 2012 Jun; 41(2):315-323.
12. Estay C, Simian D, Lubascher J et al. Ionizing radiation
exposure in patients with inflammatory bowel disease: are we
overexposing our patients? J Dig Dis 2015 Feb; 16(2):83-9.
13. Perrotta C, Pellegrino P, Moroni E et al. Five-aminosalicylic Acid:
an update for the reappraisal of an old drug. Gastroenterol Res
Pract 2015; 2015:456895.
14. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ.
Ulcerative colitis. Lancet 2012 Nov 3; 380(9853):1606-19.
15. Meyer L, Simian D, Lubascher J et al. Adverse events associated
with the treatment of inflammatory bowel disease. Rev. méd.
Chile. 2015 Jan; 143(1): 7-13.
16. Present DH. How to do without steroids in inflammatory bowel
disease. Inflamm Bowel Dis. 2000 Feb; 6(1):48-57.
17. Kuenzig ME, Rezaie A, Seow CH et al. Budesonide for
maintenance of remission in Crohn´s disease. Cochrane
Database Syst Rev 2014 Aug 21; 8: CD002913.
18. Yarur A, Abreu M, Deshpande A, Kerman D, Sussman D.
Therapeutic drug monitoring in patients with inflammatory
bowel disease. World J Gastroenterol 2014 Apr 7; 20(13):3475-
84.
19. Van der Woude CJ, Ardizzone S, Bengtson MB et al. The Second
European Evidenced-Based Consensus on Reproduction and
Pregnancy in Inflammatory Bowel Disease. J Crohns Colitis.
2014 Nov 26; 1-18.
20. Vaysse T, Carbonell F. Methotrexate in IBD: the return of the
prodigal son. J Crohns Colitis 2015 Apr; 9(4):303-4.
21. Amiot A, Peyrin-Biroulet L. Current, new and future biological
agents on the horizon for the treatment of inflammatory bowel
diseases. Therap Adv Gastroenterol. 2015 Mar; 8(2):66-82.
22. Actis GC, Pellicano R, Rosina F. Inflammatory bowel diseases:
Current problems and future tasks. World J Gastrointest
Pharmacol Ther. 2014Aug 6; 5(3):169-74.
23. Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article:
anti_adhesion therapies for inflammatory bowel disease.
Aliment Pharmacol Ther. 2014 Mar; 39(6):579-94.
24. Louis E, Dotan I, Ghosh S et al. Optimising the Inflammatory
Bowel Disease Unit to Improve Quality of Care: Expert
Recommendations. J Crohns Colitis. 2015 Aug: 9(8):685-91.
[REV. MED. CLIN. CONDES - 2015; 26(5) 663-666]